苯并[d]噻唑-4-胺 | 1123-51-9

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 苯并[d]噻唑-4-胺
• 中文别名: 4-氨基苯并噻唑；苯并噻唑-4-胺
• 英文名称: 4-aminobenzothiazol
• 英文别名: 1,3-benzothiazol-4-amine；benzo[d]thiazol-4-amine；4-Amino-benzthiazol；4-Benzothiazolamine
• CAS: 1123-51-9
• 化学式: C₇H₆N₂S
• mdl: MFCD00672135
• 分子量: 150.204
• InChiKey: DUGYIAXAVYWYOR-UHFFFAOYSA-N

物化性质

• 熔点：
  94 °C(Solv: benzene (71-43-2))
• 沸点：
  323.1±15.0 °C(Predicted)
• 密度：
  1.383±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

制备方法与用途

4-氨基苯并噻唑是一种非常有用的研究化学物质。

反应信息

• 作为反应物：
  描述：

  苯并[d]噻唑-4-胺 生成 4-溴苯并噻唑
  参考文献：
  名称：

  400.苯并噻唑的亲电取代。第二部分 氨基苯并噻唑的溴化

  摘要：

  DOI：

  10.1039/jr9650002248
• 作为产物：
  描述：

  N-(2-Chloro-6-nitro-phenyl)-formamide 在 sodiumsulfide nonahydrate 、 铁粉 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 6.0h， 生成 苯并[d]噻唑-4-胺
  参考文献：
  名称：

  Structure–activity relationships of N-phenyl-N′-benzothiazol-6-ylurea synthetic derivatives: Cytokinin-like activity and adventitious rooting enhancement

  摘要：

  Some years ago we demonstrated the cytokinin-like activity of the synthetic N-phenyl-N'-benzothiazol-6-ylurea (PBU) and a relevant adventitious rooting adjuvant activity of symmetric urea derivatives devoid of any cytokinin- or auxin-like activity per se. Here we report the synthesis and the biological activity evaluation of nine symmetric or asymmetric ureas/thioureas, structurally related to PBU. None of them show cytokinin-like activity, while we demonstrate for the first time that PBU interacts with Arabidopsis cytokinin receptor CRE1/AHK4 in a heterologous bioassay system. Among the PBU derivatives, all the symmetric ureas/thioureas show an adventitious rooting adjuvant activity in various bioassays, confirming that this activity is strictly dependent on their chemical structure. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.phytochem.2011.10.012

文献信息

• Optimization of 4-Anilinoquinolines as Dengue Virus Inhibitors
  作者：Pei-Tzu Huang、Sirle Saul、Shirit Einav、Christopher R. M. Asquith

  DOI：10.3390/molecules26237338

  日期：——

  Emerging viral infections, including those caused by dengue virus (DENV) and Venezuelan Equine Encephalitis virus (VEEV), pose a significant global health challenge. Here, we report the preparation and screening of a series of 4-anilinoquinoline libraries targeting DENV and VEEV. This effort generated a series of lead compounds, each occupying a distinct chemical space, including 3-((6-bromoquinolin-4-yl)amino)phenol (12), 6-bromo-N-(5-fluoro-1H-indazol-6-yl)quinolin-4-amine (50) and 6-((6-bromoquinolin-4-yl)amino)isoindolin-1-one (52), with EC50 values of 0.63–0.69 µM for DENV infection. These compound libraries demonstrated very limited toxicity with CC50 values greater than 10 µM in almost all cases. Additionally, the lead compounds were screened for activity against VEEV and demonstrated activity in the low single-digit micromolar range, with 50 and 52 demonstrating EC50s of 2.3 µM and 3.6 µM, respectively. The promising results presented here highlight the potential to further refine this series in order to develop a clinical compound against DENV, VEEV, and potentially other emerging viral threats.

  新兴病毒感染，包括那些由登革热病毒（DENV）和委内瑞拉马脑炎病毒（VEEV）引起的感染，构成了全球重大的健康挑战。在这里，我们报告了针对DENV和VEEV的一系列4-苯胺基喹啉类化合物库的制备和筛选工作。这一努力产生了一系列主导化合物，每个化合物占据着不同的化学空间，包括3-((6-溴喹啉-4-基)氨基)酚（12）、6-溴-N-(5-氟-1H-吲哚-6-基)喹啉-4-胺（50）和6-((6-溴喹啉-4-基)氨基)异吲哚啉-1-酮（52），对DENV感染的EC50值为0.63-0.69 µM。这些化合物库在几乎所有情况下表现出非常有限的毒性，CC50值大于10 µM。此外，主导化合物被筛选用于对抗VEEV，并在低个位数微摩尔范围内展示了活性，其中50和52的EC50分别为2.3 µM和3.6 µM。这里呈现的有希望的结果突显了进一步完善这一系列的潜力，以开发针对DENV、VEEV和潜在其他新兴病毒威胁的临床化合物。
• Novel Sulfonaminoquinoline Hepcidin Antagonists
  申请人：Buhr Wilm

  公开号：US20120214803A1

  公开（公告）日：2012-08-23

  The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

  本发明涉及新型肝铁蛋白拮抗剂，包括它们的药物组合物以及将其用作药物治疗铁代谢紊乱，特别是铁缺乏病和贫血等疾病，特别是与慢性炎症性疾病相关的贫血。
• PPAR-gamma modulator
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20030134859A1

  公开（公告）日：2003-07-17

  A compound of the following formula or a pharmacologically acceptable salt thereof: 1 wherein A represents a phenyl group or the like, B represents an aryl group or the like, X represents an oxygen atom or the like, and n represents 0 or 1. The compound is a PPAR &ggr; modulator which is a therapeutic agent for retrograde osteoporosis in which excessive differentiation of adipocytes is inhibited and formation and differentiation of osteoblasts from stem cells is facilitated, and for diabetes mellitus without characteristics such as excessive adipogenesis, liver dysfunction, vascular disorders, heart diseases and the like.

  以下化学式的化合物或其药理学上可接受的盐：其中A代表苯基或类似物，B代表芳基或类似物，X代表氧原子或类似物，n代表0或1。该化合物是一种PPAR &ggr; 调节剂，用于治疗逆行性骨质疏松症，通过抑制脂肪细胞的过度分化并促进干细胞向成骨细胞的形成和分化，以及用于糖尿病而不具有过度脂肪生成、肝功能障碍、血管紊乱、心脏疾病等特征。
• [EN] ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES<br/>[FR] AGENTS ANTIBACTÉRIENS : N (ALPHA)-AROYL-N-ARYL-PHÉNYLALANINAMIDES
  申请人：UNIV RUTGERS

  公开号：WO2015120320A1

  公开（公告）日：2015-08-13

  The invention provides compounds having activity as bacterial RNA polymerase inhibitors and antibacterial agents, as well as compositions comprising the compounds and methods for their use. Specifically, phenylalanineamide and tyrosinamide compounds are disclosed that have inhibitory activity toward mycobacterium tuberculosis RNA polymerase. Use of these compounds in the treatment o prevention of M. tuberculosis infections in a mammal, is disclosed.

  该发明提供了具有细菌RNA聚合酶抑制剂和抗菌剂活性的化合物，以及包含这些化合物的组合物和它们的使用方法。具体地，揭示了对结核分枝杆菌RNA聚合酶具有抑制活性的苯丙氨酰胺和酪氨酰胺化合物。还揭示了在哺乳动物中使用这些化合物治疗或预防结核分枝杆菌感染的方法。
• Novel selenadiazole derivatives as selective antitumor and radical scavenging agents
  作者：Ana Carolina Ruberte、Daniel Plano、Ignacio Encío、Carlos Aydillo、Arun K. Sharma、Carmen Sanmartín

  DOI：10.1016/j.ejmech.2018.07.063

  日期：2018.9

  Likewise, radical scavenging properties of the new selenadiazole derivatives were confirmed by testing their ability to scavenge DPPH radicals. Four compounds (1, 2, 8 and 9) showed potent radical scavenging activity, compound 9 being the most effective. Overall, while compound 7 was identified as the most cell growth inhibitory agent and selectively toxic to cancer cells, compound 9 proved to be the

  设计并合成了27种新颖的苯并[ c ] [1,2,5]硒二唑-5-羧酸（BSCA）衍生物。这些结构的抗增殖活性在体外针对一组五种人类癌细胞系进行了测试，其中包括前列腺癌（PC-3），结肠癌（HT-29），白血病（CCRF-CEM），肺癌（HTB-54）和乳房（MCF-7）。四种化合物（5，6，7和19）显示出有效的抑制活性与GI 50点小于10μm的值在癌细胞系中的至少一个。在源自乳房（184B5）和肺（BEAS-2B）的两种非恶性细胞系中进一步检查了这些化合物的选择性。化合物7 在MCF-7细胞中显示出有希望的抗增殖活性（GI 50 = 3.7μM），同时具有高选择性指数（SI> 27.1）。 化合物7对细胞死亡的诱导与凋亡过程无关，并且它也不影响细胞周期进程。同样，通过测试新硒代二唑衍生物清除DPPH自由基的能力也证实了其清除自由基的性能。四种化合物（1，2，8和9）显示了强的自由基清